

Table A3.2. Evaluation of the cost-effectiveness frontier of screening and isolation policies in an intensive care unit setting. Numbers refer to strategy numbers, where: 1 = baseline ‘do nothing’; 2 = universal pre-emptive isolation; 6 = universal polymerase chain reaction screening and isolation of MRSA positives; 8b = chromogenic agar screening for high risk patients (using early and late result) and isolation of MRSA positives; 9 = polymerase chain reaction screening for high risk patients and isolation of MRSA positives. ICER = incremental cost-effectiveness ratio. QALY = quality adjusted life year.

Move between strategies	Cost per admission	QALY per admission	Change in costs, ΔC (compared to previous strategy)	Change in effects, ΔE (compared to previous strategy)	Difference in Costs / Difference in Effects (ICER, cost/QALY)	Option evaluation
Stay at strategy 1	£12,661	9.1641	-	-	-	-
Or move:						
to 8b	£12,670	9.1665	£9.42	0.002445	£3,852	Under threshold
to 9	£12,708	9.1676	£37.74	0.001059	£35,627	Over threshold
to 6	£12,737	9.1683	£28.54	0.000741	£38,533	Over threshold
to 2	£12,771	9.1686	£34.19	0.000289	£118,399	Over threshold